First-in-human Phase I/Ib Study of NIZ985, a Recombinant Heterodimer of IL-15 and IL-15Rα, As a Single Agent and in Combination with Spartalizumab in Patients with Advanced and Metastatic Solid Tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER（2023）
关键词
cytokines,immunotherapy,immune checkpoint inhibitors
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要